Netupitant/Palonosetron Hydrochloride

DRUG2 trials

Sponsors

University of Rochester NCORP Research Base, Ottawa Hospital Research Institute

Conditions

Breast CarcinomaGerm Cell Cancer

Early Phase 1

A Simplified Regimen to Prevent Nausea and Vomiting Using Netupitant/Palonosetron in Germ Cell Cancer Patients Receiving Chemotherapy

Not yet recruitingNCT07662200

Ottawa Hospital Research InstituteGerm Cell Cancer

Start: 2026-08-01End: 2028-08-01Target: 10Updated: 2026-06-23

Phase 3

Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer

CompletedNCT03367572

University of Rochester NCORP Research BaseBreast Carcinoma

Start: 2018-04-19End: 2024-04-13Updated: 2025-09-25

Related Papers

Abstract PD1-09: Nausea as a Mediator of Olanzapine’s effect on Quality-of-Life Improvement in Patients Receiving Highly or Moderately Emetogenic Chemotherapy Insights from a Phase III NCORP RCT

Clinical Cancer Research2026-02-17

Nausea as a mediator of olanzapine’s effect on quality-of-life improvement: Insights from a phase III NCORP RCT.

JCO Oncology Practice2025-10-01

Impact of cancer related fatigue on quality of life of 1,262 patients with breast cancer receiving chemotherapy: A URCC NCORP nationwide phase III RCT.

Journal of Clinical Oncology2025-05-28

A nationwide double-blind phase III randomized clinical trial (RCT) of olanzapine vs. prochlorperazine for the treatment of refractory nausea in patients receiving moderately or highly emetogenic chemotherapy among NCI Community Oncology Research Program (NCORP) practices.

JCO Oncology Practice2024-09-30